David Easson, Sc.D., President,
has over 20 years experience in the biotech
industry in both private and public companies.Previously he was VP Manufacturing and
Process Development at Epic Therapeutics, Inc., a private drug delivery company
which was acquired by Baxter Healthcare Corporation. Dr. Easson was also General Manager with
Collaborative BioAlliance at their Smithfield, RI contract biopharmaceutical manufacturing
facility.Prior to that, Dr. Easson was co-founder
and Chief Operating Officer of Alpha-Beta Technology Inc., a public company
involved in the development and manufacturing of yeast derived
biopharmaceuticals.He has served on the
boards of the UMass Memorial Foundation, the Worcester Business Development
Corporation and the Juvenile Diabetes Research Foundation (JDRF) Bay State
Chapter.He also served as a Lay Review
Committee member for JDRF International.In 1993, Dr. Easson was a finalist for Ernst & Young'sNew England Region Entrepreneur of the Year
Award.He received the Mary Ann Kugel
award from JDRF in 2001.He also
received a 2006 Baxter Outstanding Technical Achievement award.Dr. Easson has a B.S. in chemical engineering
from the University of South Carolina and a Sc.D. in biochemical engineering
from MIT.
Tony Garramone, Chief Business Officer has, over his 25
yearsin bio/pharma and drug delivery
companies, demonstrated the ability to build, grow and sustain strong
organizations, and to manage these organizations to and through liquidity
events. He was President of Epic Therapeutics (acquired by Baxter Healthcare
Corp) and was a founding member of Transgenic Sciences, Inc., which he helped
take public.
Craig C. Mello, Ph.D.is a Scientific Founder and Scientific Advisory Board Member of Cadrus.
He is a co-recipient of the 2006 Nobel Prize in Medicine for the discovery of
RNAi.Dr. Mello is the Blais University
Chair in Molecular Medicine at the University of Massachusetts Medical School,
a Howard Hughes Investigator and a member of the National Academy of Sciences.
In 2006, he was named the inaugural recipient of The Dr. Paul Janssen Award for
Biomedical Research by Johnson & Johnson and was the co-recipient of the
Paul Ehrlich and Ludwig Darmstaedter Prize. Dr. Mello was also the co-recipient
of the National Academy of Sciences Award in Molecular Biology and the Wiley
Prize in the Biomedical Sciences from Rockefeller University in 2003. He was a
postdoctoral fellow at the Fred Hutchinson Cancer Research Center and in 1995,
was named a Pew Scholar in the Biomedical Sciences. Dr. Mello received his B.S.
in Biochemistry from Brown University in 1982 and his Ph.D. in Cellular and
Developmental Biology from Harvard University in 1990.
Michael Czech, Ph.D.is a Scientific Founder and Scientific Advisory Board Member of Cadrus.Heis Professor and Chair, Program in
Molecular Medicine, at the University of Massachusetts Medical School. Dr.
Czech has authored over 250 papers in the field of insulin action, and was
awarded the Eli Lilly Award for Diabetes Research, the 1998 Elliot P. Joslin
Medal in diabetes research and the 2000 Banting Medal of the American Diabetes
Association. He was a member of the Cell Biology and Regulation Review Panel of
the Howard Hughes Medical Institute from 1994-1998, and served as a member of
the Endocrinology Study Section of the National Institutes of Health. Dr. Czech
received a B.A. from Brown University in 1967, a M.A. from Duke University in
1969 and received his Ph.D. in Biochemistry from Brown University in 1972.
Gary
Ostroff, Ph.D. is a Scientific
Founder and Scientific Advisory Board Member of Cadrus. He is currently
a Professor of Molecular Medicine at the University of Massachusetts Medical
School.Dr. Ostroff has over 25 years of
research and development (R&D) experience in the biopharmaceutical,
functional food and dietary supplement industries. He has served as Vice
President of R&D for several US companies, including Biothera, Amerifit
Brands and Alpha-Beta Technology. He has also served as an international
scientific advisor/consultant for Eden Research, Biotec Pharmacon, Biorigin,
and Antigen Express. Dr. Ostroff's scientific
accomplishments encompass the development of carbohydrate and protein
therapeutics, diagnostics, target discovery, assay development and small
molecule drug screening from discovery through Phase III clinical
studies. The current focus of his lab is developing the Glucan Particle
Delivery Technology for oral oligonucleotide, vaccine and small molecule
applications.
Cadrus Therapeutics, Inc. 67 Millbrook Street Suite 422 Worcester, MA 01606